Benserazide, (S)- | 26652-10-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Benserazide, (S)-
• 英文别名: (2S)-2-amino-3-hydroxy-N'-[(2,3,4-trihydroxyphenyl)methyl]propanehydrazide
• CAS: 26652-10-8
• 化学式: C₁₀H₁₅N₃O₅
• mdl: MFCD00078571
• 分子量: 257.24
• InChiKey: BNQDCRGUHNALGH-LURJTMIESA-N

物化性质

• 沸点：
  574.2±50.0 °C(Predicted)
• 密度：
  1.541±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  148
• 氢给体数：
  7
• 氢受体数：
  7

文献信息

• Synthesis and Surface Functionalization of Particles
  申请人：Board of Trustees of The University of Alabama

  公开号：US20140179941A1

  公开（公告）日：2014-06-26

  Provided are methods of controlling the shape and surface chemistry of nanoparticles, particularly ferrite nanoparticles. Methods for preparing non-spherical ferrite nanoparticles, including nanocubes, nanobars, nanoplates, and nanoflowers, are described. Also provided are methods of functionalizing the surface of metal and metal oxide particles. The surface functionalization methods do not require the use of chemical linkers and/or additional reagents, and permit the facile conjugation of a range of molecules, including bioactive agents, to the surface of particles.

  提供了控制纳米颗粒形状和表面化学性质的方法，特别是铁氧体纳米颗粒。描述了制备非球形铁氧体纳米颗粒的方法，包括纳米立方体、纳米棒、纳米板和纳米花。还提供了功能化金属和金属氧化物颗粒表面的方法。表面功能化方法不需要使用化学连接剂和/或额外试剂，并允许轻松地将一系列分子，包括生物活性剂，连接到颗粒表面。
• Synergistic pharmaceutical compositions, their production and use
  申请人：CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT.

  公开号：EP0146363A2

  公开（公告）日：1985-06-26

  The invention relates to a synergistic pharmaceutical composition, which comprises as an active ingredient a combination of 1-phenylalanine and (-)-deprenyl [(-)-N-(1-phenylisopropyl)-N-methyl-N-propinylamine hydrochloride] and optionally carbidopa [3-(3,4-dihydroxyphenyl)-2-hydrazino-2--methyl-propionic acid monohydrate] or benzerazide [N-(DL--seryl)-N'-(2,3,4-trihydroxybenzyl)-hydrazinel in association with conventional inert, non-toxic solid or liquid pharmaceutical carriers. The invention further relates to the preparation of these compositions and to the use thereof for the treatment of depressive symptoms.

  本发明涉及一种增效药物组合物，其活性成分包括1-苯丙氨酸和(-)-癸烯基[(-)-N-(1-苯基异丙基)-N-甲基-N-丙胺盐酸盐]的组合，以及可选的卡比多巴[3-(3,4-二羟基苯基)-2-肼基-2-甲基丙酸一水合物]或苯泽拉嗪[N-(DL-丝氨酰)-N'-(2,3,4-三羟基苄基)-肼基]与常规惰性、无毒固体或液体药物载体的组合。 本发明还涉及这些组合物的制备及其用于治疗抑郁症状的用途。
• Synergistische Kombination von Decarboxylasehemmern und L-Dopa-Pellets
  申请人：ASTA Medica Aktiengesellschaft

  公开号：EP0324947A1

  公开（公告）日：1989-07-26

  Synergistische Kombination von L-Dopa-Pellets und Decarboxylase­hemmern als Arzneimittel gegen Parkinsonsche Krankheit.

  左旋多巴颗粒与脱羧酶抑制剂的协同组合，作为治疗帕金森病的药物。
• Novel uses for drugs targeting glutamine synthetase
  申请人：NewThera

  公开号：EP1752143A1

  公开（公告）日：2007-02-14

  The present invention relates to novel therapeutic uses of tianeptine, salts, isomers, prodrugs, metabolites and structural analogs thereof. Furthermore, the present invention relates to the use of tianeptine, salts, isomers, pro-drugs, metabolites and structural analogs thereof, in obtaining methods of screening and of developing drugs. Finally, the present invention relates to the novel therapeutic use of other glutamine synthetase (GS) ligands and to the use of these ligands in obtaining methods for screening and developing drugs.

  本发明涉及噻奈普汀、其盐类、异构体、原药、代谢物和结构类似物的新型治疗用途。此外，本发明还涉及噻奈普汀、其盐类、异构体、原药、代谢物和结构类似物在获得药物筛选和开发方法中的用途。最后，本发明涉及其他谷氨酰胺合成酶（GS）配体的新型治疗用途，以及使用这些配体获得筛选和开发药物的方法。
• Composition comprising a dopamine agonist and an L-DOPA derivative for treating Parkinson's disease
  申请人：CDRD Berolina AB

  公开号：EP2918266A1

  公开（公告）日：2015-09-16

  Disclosed is a pharmaceutical composition comprising i) a dopamine agonist and ii) a L-DOPA derivative in combination in form of a liquid preparation. The pharmaceutical composition comprises a dopamine agonist selected from the group comprising apomorphine, ropinirole, rotigotine, pramipexole, and piribedile and a L-DOPA derivative selected from L-DOPA, selectively and/ or partially deuterated L-DOPA derivatives, as well as physiologically acceptable salts of the aforementioned L-DOPA derivatives. The pharmaceutical composition is provided in a form of a parental application selected from infusions, injections or an application via a gastric tube. The pharmaceutical composition is used for the treatment of Parkinson's disease, of restless leg syndrome, of dystonia, for inhibiting prolactin secretion, for stimulating the release of growth hormones, for the treatment of neurological symptoms of chronic manganese intoxication, of amyotrophic lateral scleroses and of multiple system atrophy.

  所公开的药物组合物包含 i) 多巴胺激动剂和 ii) L-DOPA 衍生物 以液体制剂形式组合。 该药物组合物包括选自阿朴吗啡、罗匹尼罗、罗替戈汀、普拉克索和吡贝地尔的多巴胺激动剂和选自 L-DOPA、选择性和/或部分氚化 L-DOPA 衍生物的 L-DOPA 衍生物，以及上述 L-DOPA 衍生物的生理上可接受的盐。 药物组合物以亲体应用的形式提供，可选择输液、注射或通过胃管应用。 该药物组合物可用于治疗帕金森病、不安腿综合征、肌张力障碍、抑制催乳素分泌、刺激生长激素释放、治疗慢性锰中毒、肌萎缩侧索硬化症和多系统萎缩的神经症状。